Tag: Alnylam Pharmaceuticals
January 21, 2019
Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an...
November 25, 2018
What is In-licensing?
In-licensing may be pharma’s preferred mode of business development these days. Should that impact your investment strategy? October 15, 2018
Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application
Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA),... September 14, 2018
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO... August 21, 2018
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase...
August 13, 2018
Alnylam Pharma Receives FDA Approval for Onpattro
On Friday, Alnylam Pharmaceuticals received US Food and Drug Administration approval for Onpattro (patisiran). August 13, 2018